The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Levels of Adherence Required for Virologic Suppression Among Newer Antiretroviral Medications
Abstract
Objective: To determine the adherence levels needed for HIV virologic suppression with newer antiretroviral (ARV) medications, including darunavir, etravirine, and raltegravir. Data Sources: Literature searches of PubMed, MEDLINE (1950-October 2010), and Google Scholar were performed using the following hey words in multiple combinations: antiretroviral, HIV, AIDS, adherence, darunavir, raltegravir, and etravirine. A review of the bibliographies of retrieved articles was performed to identify additional references. Study Selection and Data Extraction: All articles in English were identified from the data sources and evaluated. Studies that did not state names of medications or drug classes studied were excluded. Data Synthesis: There are differing levels of adherence needed to maintain virologic suppression, depending on the ARV class used. The adherence level needed for unboosted protease inhibitors (Pls) has been established as greater than 95%, but recent studies have shown that greater than 80% adherence to boosted Pls may be sufficient. Nonnucleoside reverse transcriptase inhibitors (NNRTIs) could require lower adherence rates than boosted Pls; however, study results are varied and NNRTIs carry a potential for developing resistance with nonadherence. Studies assessing the adherence needed for raltegravir have yet to be performed. Conclusions: Studies have shown differing levels of adherence needed among ARV classes of medications. With the advent of boosted Pls and potent medications, the amount of adherence needed has dropped since the 1990s. Although the current data are useful, there are discrepancies in the results due to the methods of adherence measurement. Knowing what adherence levels are needed is valuable in helping to determine the optimal ARV regimen for patients, given their adherence barriers. This knowledge can also help determine which patients require in-depth adherence counseling. Further research with a reliable method of measuring adherence is essential to determine adherence levels needed for newer ARV medications, including darunavir, etravirine, and raltegravir.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., Wu, A. W., & PATIENT CARE COMMITTEE & ADHERENCE (2000) · AIDS Care · doi:10.1080/09540120050042891 · Cited by 1,428
Cited by
Nachega, J. B., Uthman, O. A., Anderson, J., Peltzer, K., Wampold, S., Cotton, M. F., Mills, E. J., Ho, Y.-S., Stringer, J. S. A., McIntyre, J. A., et al. (2012) · AIDS · doi:10.1097/qad.0b013e328359590f · Cited by 488
Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data
Byrd, K. K., Hou, J. G., Hazen, R., Kirkham, H., Suzuki, S., Clay, P. G., Bush, T., Camp, N. M., Weidle, P. J., Delpino, A., et al. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002142 · Cited by 285
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy
Viswanathan, S., Justice, A. C., Alexander, G. C., Brown, T. T., Gandhi, N. R., McNicholl, I. R., Rimland, D., Rodriguez-Barradas, M. C., & Jacobson, L. P. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000643 · Cited by 98
Kekwaletswe, C., & Morojele, N. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s55547 · Cited by 47
Wechsberg, W. M., Bonner, C. P., Zule, W. A., van der Horst, C., Ndirangu, J., Browne, F. A., Kline, T. L., Howard, B. N., & Rodman, N. F. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.10.036 · Cited by 32
Metadata
- Authors
- Kobin, A. B., & Sheth, N. U.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2011-03
- Volume
- 45
- Issue
- 3
- Pages
- 372-379
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2096686116
- Cited by
- 167
- References
- 1
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.